P soriatic arthritis (PsA) is an inflammatory joint disease associated with the presence of cutaneous psoriasis. PsA is characterized by a negative rheumatoid factor (RF) and the presence of peripheral and axial joint involvement.
The existence of PsA as a distinct entity has been controversial and the lack of a validated classification and/or diagnostic criteria has compounded the issue. The claim has been made that PsA is the coincident occurrence of a seronegative arthropathy and/or rheumatoid arthritis (RA) and cutaneous psoriasis. It should be pointed out, however, that PsA has some distinctive characteristics such as distal interphalangeal (DIP) involvement, asymmetric peripheral and axial joint involvement, and nail disease, which allow its distinction from other inflammatory arthritides.
More recently, serologic testing for anticyclic citrullinated peptide (anti-CCP) antibodies has been reported to be highly sensitive and specific for RA 1 and absent in a variety of disorders associated with a high frequency of RF positivity and/or RA-like clinical presentation, including hepatitis Cassociated polyarthritis, 2 juvenile rheumatoid arthritis, 3 palindromic rheumatism, 4 and Sjögren syndrome. 5 Furthermore, anti-CCP antibodies have been noted to be of great clinical use and prognostic significance for the development of RA in patients with undifferentiated arthritis 6 or early RA, even before the appearance of erosions and RF.
There are recent reports describing the frequency of anti-CCP antibodies in PsA. 8 -10 The presence of anti-CCP antibodies in psoriatic patients with or without manifestation of joint inflammation has been studied by Alenius et al, 11 who showed that anti-CCP antibodies were present in 11 patients with psoriatic arthritis as opposed to only one patient with psoriasis. The aims of this study were to determine the seropositivity of anti-CCP antibodies in patients with psoriasis and PsA to further assess its clinical value and also to compare it with that of patients with inflammatory (undifferentiated ͓UA͔, RA) and noninflammatory (osteoarthritis ͓OA͔) arthritides.
PATIENTS AND METHODS
Patients with cutaneous psoriasis were evaluated for demographic and laboratory characteristics, including age, sex, date of psoriasis onset, family history of psoriasis, treatment, and Psoriatic Assessment of Skin Index (PASI) that was performed by a dermatologist (CG). This group of patients was evaluated for the presence of PsA by 2 senior rheumatologists (LRE and RV).
Patients
Patients with PsA were diagnosed according to the Moll and Wright criteria. Patients were evaluated for tender and swollen joints, spinal involvement, both clinically and by x-ray, acute-phase reactants (C-reactive protein and erythrocyte sedimentation rate), family history of psoriasis or PsA, treatment used, and PASI.
A group of patients with RA according to the American College of Rheumatology Criteria (ACR) were studied as well. To calculate sensitivity of the test in patients with PsA, a group of healthy controls was studied.
To study the behavior of these antibodies in noninflammatory arthritides, a group of 41 patients with OA was also studied. Patients with OA fulfilled the ACR criteria for OA of the knee, hand and hip, pain, aching and stiffness of these regions, with morning stiffness of less than 30 minutes, negative RF, age more than 50 years, erythrocyte sedimentation rate less than 20 mm Hg, and radiologic changes of OA, joint space narrowing, and osteophytes. [12] [13] [14] To assess the prognostic significance of anti-CCP antibodies in patients with UA, 43 of these patients were studied. These patients were negative for RF at baseline. None of the patients had personal or family history of spondyloarthropathy (SpA) or psoriasis. A second determination for anti-CCP antibodies and RF was performed within 5 years of initial diagnosis.
Laboratory Methods
After informed consent, we obtained 10 mL of blood by venipuncture. Serum was obtained and stored at Ͻ20°C before testing. Anti-CCP was tested using a second-generation enzyme-linked immunosorbent assay for the detection of anti-CCP from INOVA Diagnostic, Inc. (San Diego, CA) following the manufacturer's instructions establishing a cutoff point of Ͼ20 for a positive test. Rheumatoid factor was evaluated by nephelometry.
Protocol was reviewed and approved by the Institutional Review Board at the military hospital, Bogota, Colombia, and Louisiana State University, New Orleans, Louisiana.
Statistical Analysis
Titers of anti-CCP antibodies were compared between groups using an unpaired t test. P Ͻ 0.05 was established as statistically significant.
RESULTS
We studied 106 patients with cutaneous psoriasis without joint involvement. Fifty-five were women and 51 were men. The mean age was 42.87 Ϯ 17.71 years and the mean disease duration was 5.3 Ϯ 2.10 years. The mean PASI score was 11.85 Ϯ 11.41. None of the patients were on biologic therapy. The median titer of anti-CCP antibodies was 3.402 (interquartile range, 2.375-5.83). According to the cutoff value advised by the manufacturer (Ͼ20 units), none of the patients with cutaneous psoriasis had positive anti-CCP antibodies.
Seventy-two patients with PsA were studied. Forty-one were women and 31 were men. The mean age was 47.7 years (range, 39 -72 years) and mean disease duration was 9 years (range, 6 -14 years). The pattern of joint involvement in 44 patients with the oligoarticular form was 19 with polyarticular (RA-like), 5 psoriatic spondyloarthropathy, one monoarticular PsA, and 3 arthritis mutilans. The mean PASI score was 7.1. Only 2 patients had a low titer positive RF. All but one patient was receiving treatment, 69 were on diseasemodifying antirheumatic drugs (DMARDs) and 22 were on anti-TNF-␣ inhibitors in addition to DMARDs.
The median of anti-CCP antibodies in patients with PsA as a group was 7.168 (interquartile range, 5.828 -11.46). Only 7 of 72 patients with PsA were positive for anti-CCP antibodies with titers higher than 20. The median of anti-CCP in these patients who were positive for anti-CCP with PsA was 133.6 (interquartile range, 86.49 -168.9). Only one of the patients with positive anti-CCP had positive RF and 5 had polyarticular joint involvement. Approximately 5% of our patients with PsA had enthesitis and 7% dactylitis. Demographic and clinical characteristics of patients with PsA with positive anti-CCP antibodies are summarized in Table 1 and in more detail in Table 2 , which contains characteristics of patients with PsA who were positive for anti-CCP. Note that 4 of the anti-CCP-positive patients also had DIP involvement and 2 had dactylitis.
When we compared the titers of anti-CCPs antibodies in patients with PsA and patients with psoriasis, we found clear and statistically significant differences (P ϭ 0.001; 95% confidence interval, Ϫ23.67 to Ϫ7.887; Fig. 1 ).
Patients With Osteoarthritis and Rheumatoid Arthritis
Forty-one patients with OA were studied. Thirty-five were female and 6 were males. Six of 41 (14.6%) patients with OA studied had positive anti-CCP antibodies. The median titter for anti-CCP antibodies was 7.388 (interquartile range, 6.25-11.6). Forty-one patients with RA were analyzed; 32 of 41 were positive for anti-CCP antibodies with a mean Ϯ standard deviation of 80.61 Ϯ 55.52 (data not shown).
Patients With Undifferentiated Arthritis
Of the 43 patients with UA, 38 were women and 5 were men. Mean age was 40.5 years. None of the patients was positive for RF at onset. None of the patients exhibited psoriatic rash or enthesitis. Five patients were positive for anti-CCP antibodies, 4 at onset. One patient who was previously negative had a positive anti-CCP testing at follow up and developed RA according to the ACR criteria. None of the patients developed PsA to date (data not shown).
DISCUSSION
There are few reports of the presence of anti-CCP antibodies in patients with PsA. This is an important aspect in the differential diagnosis between RA and PsA, especially the polyarticular form, which is very similar to RA and possesses many diagnostic problems.
A low frequency of anti-CCP antibodies in patients with PsA was confirmed in our study, according to previous reports. 8 -11 Our findings confirm a high specificity of anti-CCP antibodies for the diagnosis of RA, but also demonstrate their presence, albeit in low frequency and titers in other arthritides, including PsA, OA, and UA. We found that 7 of 72 patients with PsA were positive for anti-CCP, whereas all patients with cutaneous psoriasis were negative for anti-CCP. Similar findings were described by Alenius et al 11 who studied the presence of anti-CCP in patients with psoriasis with or without joint inflammation. The source of anticitrullinated protein antibodies (ACPAs) has been proposed to be the synovium. The antigenic determinant recognized by these antibodies is the unusual amino acid citrulline. Citrulline can be generated by posttranslational modification of arginine residues. This modification is catalyzed by peptidyl arginine deiminase. However, the mere presence of deaminated fibrin in synovium does not fully explain the RA-specific induction of ACPAs, because citrullinated fibrin was detected equally in inflamed synovium in non-RA patients and in animal models of arthritis, in which deaminated fibrin does not induce ACPAs. The presence of citrullinated proteins in the synovial tissue has been reported to be nonspecific for RA. This expression has also been described in patients with inflammatory OA, reactive arthritis, and crystal associateddisease. Furthermore, there is also a lack of correlation between the expression of serum anti-CCP antibodies and synovial membrane staining in all studied groups. This led the authors to conclude that the presence of citrullinated proteins in the inflamed synovium could be the result of an inflammatory phenomenon. 15 De Rycke et al demonstrated the presence of extracellular staining of ACPAs in the synovium of patients with spondyloarthropathies and osteoarthritis. 16 The authors seem to agree that the most common subtype of PsA observed in these anti-CCP-positive patients were women with polyarticular involvement; in our study, 17 are useful in the distinction between RA and PsA RA-like; according to these criteria, Vander Cruyssen et al concluded in a study of the presence of anti-CCPs antibodies in patients with PsA that it was improbable that the high prevalence of anti-CCP antibodies resulted solely from concomitant psoriasis and RA or from misclassification.
The frequency of anti-CCPs antibodies was higher in the group of patients with RA. Like in other instances, these antibodies have demonstrated high specificity for the diagnosis of RA. In the case of PsA, whether or not the presence of anti-CCP antibodies is a coincidence of 2 common diseases in whites is a possibility; however, in our patients, only one of the anti-CCP-positive patients was also positive for RF, similar to Karendowych et al. 10 In conclusion, a low frequency of anti-CCPs antibodies is found in patients with PsA of as well as in patients with OA and undifferentiated arthritis, and this allows a distinction of these groups of disorders with RA. Further studies, however, of a prospective nature and with larger number of patients may be necessary to define the role of these antibodies in disorders other than RA.
